Flutamide (Euflex®)

Common name: Flutamide
Brand name: Euflex®
 

What is Flutamide?

Flutamide is a hormone antagonist that is used to treat advanced (metastatic) prostate cancer. It works by slowing or stopping the growth of prostate cancer cells by reducing the amount of testosterone in the body.
 

How is Flutamide administered?

Flutamide is administered orally as a tablet.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received flutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Breast swelling
  • Diarrhea
  • Difficulties sleeping
  • Drowsiness
  • Headaches
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Nausea / vomiting
  • Reduced sex drive (low libido)
 

Is Flutamide covered in my province or territory?*

Flutamide is covered by all provincial/territorial drug programs.


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=19458

 
Last Reviewed: July 2017

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive